BEAM THERAPEUTICS INC. - COMMON STOCK

25.38

03-January-25 16:45:00

15 minutes delayed

Stocks

+0.68

+2.75%

Today's range

24.66 - 26.20

ISIN

N/A

Source

NASDAQ

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

17 Dec 2024 07:00:00 By Nasdaq GlobeNewswire
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

08 Dec 2024 13:45:00 By Nasdaq GlobeNewswire
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

07 Dec 2024 11:30:00 By Nasdaq GlobeNewswire
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

06 Dec 2024 07:00:00 By Nasdaq GlobeNewswire
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

04 Dec 2024 07:00:00 By Nasdaq GlobeNewswire
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

12 Nov 2024 16:01:00 By Nasdaq GlobeNewswire
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 09:00:00 By Nasdaq GlobeNewswire
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

05 Nov 2024 06:30:00 By Nasdaq GlobeNewswire
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

29 Oct 2024 06:30:00 By Nasdaq GlobeNewswire
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

06 Aug 2024 06:30:00 By Nasdaq GlobeNewswire
Beam Therapeutics Announces Transition of Chief Financial Officer

15 Jul 2024 06:30:00 By Nasdaq GlobeNewswire
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

26 Jun 2024 06:30:00 By Nasdaq GlobeNewswire
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

14 Jun 2024 03:00:00 By Nasdaq GlobeNewswire
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

30 May 2024 06:30:00 By Nasdaq GlobeNewswire
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

14 May 2024 16:00:00 By Nasdaq GlobeNewswire
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

08 May 2024 06:30:00 By Nasdaq GlobeNewswire
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

07 May 2024 06:30:00 By Nasdaq GlobeNewswire
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

26 Mar 2024 06:30:00 By Nasdaq GlobeNewswire
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

28 Feb 2024 06:30:00 By Nasdaq GlobeNewswire
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

27 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

<<
<
1
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.